Quantcast
Home > Quotes > EXEL
EXEL

Exelixis, Inc. Common Stock (EXEL) Quote & Summary Data

$18.12
*  
0.45
2.55%
Get EXEL Alerts
*Delayed - data as of Nov. 21, 2018 11:27 ET  -  Find a broker to begin trading EXEL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    EXEL Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 18.11 / $ 18.12
1 Year Target
28
Today's High / Low
$ 18.19 / $ 17.7742
Share Volume
740,596
50 Day Avg. Daily Volume
4,071,901
Previous Close
$ 17.67
52 Week High / Low
$ 32.20 / $ 13.42
Market Cap
5,417,574,406
P/E Ratio
15.36
Forward P/E (1y)
13.59
Earnings Per Share (EPS)
$ 1.18
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.95

Intraday Chart

Shares Traded

Share Volume:
740,596
50 Day Avg. Daily Volume:
4,071,901

P/E Ratio

P/E Ratio:
15.36
Forward P/E (1y):
13.59
Earnings Per Share (EPS):
$ 1.18

Trading Range

The current last sale of $18.12 is 35.02% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 18.19 $ 32.20
 Low: $ 17.7742 $ 13.42

ETFs with EXEL as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.89% First Trust Amex Biotech Index Fund (FBT) -8.26 (-5.90%)
2.04% Invesco Russell MidCap Pure Growth ETF (PXMG) -3.56 (-7.27%)
1.64% SPDR Series Trust SPDR S&P Biotech ETF (XBI) -18.74 (-19.69%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Item 1. Business Overview Exelixis, Inc. ("Exelixis," "we," "our" or "us") is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET: CABOMETYX® (cabozantinib) tablets approved for advanced renal cell carcinoma, or RCC, and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC® (cobimetinib) tablets, is a formulation of cobimetinib and is an inhibitor of MEK, marketed under a collaboration with Genentech, Inc.  ... More ...  


Risk Grade

Where does EXEL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 17.86
Open Date:
Nov. 21, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x